Cargando…
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.
Results using the same drug in phase II studies of treatment in ovarian cancer vary widely. An analysis of five phase II studies with a total of 93 patients was carried out to determine whether factors other than the efficacy of the drug affect response. The drugs for the phase II studies were chose...
Autores principales: | Blackledge, G., Lawton, F., Redman, C., Kelly, K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247161/ https://www.ncbi.nlm.nih.gov/pubmed/2713253 |
Ejemplares similares
-
A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
por: Smith, D. B., et al.
Publicado: (1988) -
A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer.
por: Kehoe, S., et al.
Publicado: (1994) -
Predicting response to chemotherapy for patients with epithelial ovarian cancer using urinary polyamine excretion patterns.
por: Lawton, F. G., et al.
Publicado: (1990) -
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
por: Nurgat, Z A, et al.
Publicado: (2005) -
Phase II trial of trimelamol in refractory ovarian cancer.
por: Judson, I. R., et al.
Publicado: (1991)